title: Kawasaki disease in Mongolia: results from 2 nationwide retrospective surveys, 1996-2008.
abstract: BACKGROUND
  Kawasaki disease (KD) has been reported in many countries. However, the incidence of KD in Mongolia is not known. This is the first report of incident cases of KD in Mongolia, which were identified using data from 2 nationwide surveys.
  
  
  METHODS
  Two nationwide retrospective surveys were conducted: medical histories were collected from patients aged 0 to 16 years who were hospitalized countrywide between 1996 and 2008. Hospital records for these patients were also reviewed. Nationwide training seminars on KD were conducted before each survey.
  
  
  RESULTS
  For the nationwide surveys, the participation rates among all hospitals with pediatric wards were 97% and 94%. Inpatient medical histories from 1996 through 2008 were reviewed, and, among children younger than 16 years, 9 patients with KD were investigated. The age of KD patients ranged from 1.4 to 14 years; 7 of 9 patients were male. Six (67%) patients fulfilled all 6 clinical diagnostic criteria; the other 3 (33%) were defined as having KD based on the presence of 5 such criteria. Fever persisting 5 or more days, bilateral conjunctival congestion, and changes of the lips and oral cavity were the most common symptoms, and cervical lymphadenopathy was the least common symptom. Cardiac sequelae developed in 5 of the patients, 4 of whom were older than 10 years.
  
  
  CONCLUSIONS
  The results of these nationwide surveys reveal that KD cases do exist in Mongolia. However, knowledge of KD among Mongolian pediatricians is likely to be poor. Thus, there is a need to augment their understanding to improve management of KD patients. Further studies are crucial to clarify the epidemiologic characteristics of KD in Mongolia.
authors.affiliation: Department of Epidemiology and Biostatistics, School of Public Health, Health Sciences University of Mongolia, Mongolia. davaalham@yahoo.com
authors.forename: Dambadarjaa
authors.initials: D
authors.lastname: Davaalkham
authors.forename: Yosikazu
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Davaakhuu
authors.initials: D
authors.lastname: Baigalmaa
authors.forename: Gombojav
authors.initials: G
authors.lastname: Davaa
authors.forename: Ochir
authors.initials: O
authors.lastname: Chimedsuren
authors.forename: Nyamjav
authors.initials: N
authors.lastname: Sumberzul
authors.forename: Tserenkhuu
authors.initials: T
authors.lastname: Lkhagvasuren
authors.forename: Ritei
authors.initials: R
authors.lastname: Uehara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yanagawa
authors.forename: Tomisaku
authors.initials: T
authors.lastname: Kawasaki
mesh_terms: D000293:Adolescent; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002983:Clinical Competence; D005260:Female; D006306:Health Surveys; D006776:Hospitals, Pediatric; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D015994:Incidence; D007223:Infant; D008297:Male; D008986:Mongolia / Q000453:epidemiology; D009080:Mucocutaneous Lymph Node Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D012189:Retrospective Studies; D018570:Risk Assessment; D011795:Surveys and Questionnaires
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D001241:Aspirin